Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Customized |
Still deciding? Get samples of US$ 50/Bag
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Analysis Item |
Specification |
Result |
Assay(SOD Activity) |
≥3000u/mg |
3103u/mg |
Protein |
>80% |
85% |
Appearance |
Light Blue to White powder |
Conforms |
Odor |
Characteristic |
Conforms |
Taste |
Characteristic |
Conforms |
Sieve Analysis |
100% pass 100 mesh |
Conforms |
Moisture Content |
NMT 3.0% |
2.20% |
Arsenic(As) |
NMT 1.0mg/kg |
Conforms |
Lead(Pb) |
NMT 1.5mg/kg |
Conforms |
Total Plate Count |
30000cfu/g Max |
Conforms |
P.aeruginosa |
Absent |
Absent |
S.aureus |
Absent |
Absent |
Salmonella |
Absent |
Absent |
E.Coli |
Negative |
Negative |
Staphylococcus |
Negative |
Negative |
Description:
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
Function